← SGLT2 inhibitors × kidney outcomes

TrialJournal of the American Society of Nephrology : JASN2020

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.

Megumi Oshima et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT01032629. The trial’s primary report, PMID 28605608, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 10,142 people · 2020

Not counted

Lowered kidney outcomes

−39%−55% to −17%

Bigger than 7 in 10 on the map

As reported

RR 0.61, 95% CI 0.45–0.83

Not counted

Lowered kidney outcomes

−30%−43% to −14%

Bigger than 6 in 10 on the map

As reported

RR 0.70, 95% CI 0.57–0.86

Not counted

Lowered kidney outcomes

−19%−29% to −7%

Bigger than 4 in 10 on the map

As reported

RR 0.81, 95% CI 0.71–0.93

Three numbers in the abstract

the abstract, start to end

… attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR …

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
RR 0.610.45–0.83
Kidney outcomes
RR 0.700.57–0.86
Kidney outcomes
RR 0.810.71–0.93
SGLT2 inhibitorsKidney outcomes
1 / 3

10 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

NCT01032629phase 34,330 enrolled2009a later paper about itNCT01989754phase 45,813 enrolled2014
Full record →Abstract, authors, funding and every citing paper · PMID 32694216